into the striatum have shown that SI transplants give rise to grafts that are very similar to primary human fetal transplants. In contrast, S2 transplants give rise to grafts that shrink with time as cells migrate out from them.
We are currently assessing the fate of S3 transplants.
Although small, we have consistently found dopamine neurons within these transplants that in some cases are numerous enough to lead to functional effects. Interest ingly, we have also shown a protective effect of progeni tor cells on primary dopamine neurons. Thus, co-graft ing progenitor cells with primary cells may be a novel method for increasing the survival of dopamine neurons in clinical trials. These precursor cell populations were transplanted into a rat quinolinate lesion model of Huntington's dis ease. Other experimental groups received grafts of pri mary striatal tissue, which had been stored in a commer cial hibernation medium. All animals were allowed to survive for 12 weeks postgrafting under immunosupression with cyclosporin A. Expanded precursor cells sur vived robustly to form large discrete graft masses within the caudate-putamen. Neuronal nuclei were distributed evenly throughout the grafts, with glial elements inter posed among them. Survival of hibernated tissue was much more variable; grafts were heterogenously cellular and often showed histological signs of an ongoing rejec tion process. Enzyme histochemistry for AChE activity and immunochemistry for DARPP-32 demonstrated that expression of characteristic mature striatal phenotypes was limited in both expanded and hibernated grafts.
TRANSPLANTATION OF EXPANDED XENOGE NEIC NEURAL PRECURSORS INTO RODENT MODELS OF NEURODEGENERATIVE DISEASE
Graft-derived neuronal projections were visualized by the use of an antibody directed against the human spe cific isoform of tau. Both expanded and hibernated tis sue grafts projected diffusely in host white matter tracts, although in this study there was no evidence that out growth was directed solely and specifically to normal striatal targets.
In separate studies, expanded neural precursor cells derived from other discordant species have been trans planted into a rat model of Parkinson's disease, and show similar robust survival, neuronal differentiation, and extensive fiber outgrowth.
These results support the proposition that expanded neural precursors may have promise as an alternative to primary fetal tissue for neuronal cell replacement strate gies in neurodegenerative diseases. hippocampal lesions show profound deficits in condi tional (CD), but not simple (SD) discrimination tasks. In order to see whether cognitive improvements occur after grafts of fetal CA1 or conditionally immortalized MHP36 cells, both of which are functionally effective in rats with CA1 cell loss, 18 common marmosets (Callithrix jacchus) were trained to discriminate between re warded and nonrewarded objects (SD) and between pairs of objects signifying reward on the left or right (CD). After bilateral infusion of NMDA into CA1 (0.12 M, 0.7 pl/site, 5 sites), animals were assigned to groups of comparable impairment in recall of CDs. Graft groups received 4-ul deposits (22-23,000 cells/ul) within the 5 lesion sites, of either fetal (E94-6) CA1 cells (n = 4) or MHP36 cells (« = 4: treated with 10 mg/kg cyclosporin 5 times/week). There were five intact and five lesioned controls. Six to 12 weeks after transplantation animals were tested for SD and CD retention, and then trained with four new CD tasks. Animals that did not reach cri terion (27/30 correct choices) in 300 trials moved to the next task.
PRIMARY FETAL AND CONDITIONALLY IM MORTALIZED CELL LINE GRAFTS PROMOTE
Lesioned marmosets were substantially impaired in retention of CD, but not SD, tasks and learned new CDs with difficulty. Marmosets with both fetal and MHP36 grafts, though previously impaired, remembered CD tasks as well as intact controls. Grafted animals were slow to learn the first new CD, but thereafter progressed at control level, suggesting an increase in graft efficacy with time and/or training. Lesions resulted in ventricular enlargement, substantial CA1 pyramidal cell loss, and intense GFAP reactivity. Nissl-stained fetal grafts either formed lobules attached to the CA1 ventricular margin or clustered within lesion sites. In contrast, MHP36 grafts, identified by P-galactosidase, migrated from the site of implantation throughout the lesioned area, where they dispersed evenly, like normal CA1 cells, displaying both neuronal and glial morphologies.
Thus, CA1 lesions produced long-lasting CD deficits, against which to assess graft effects. Improvement was equivalent with fetal and MHP36 grafts, demonstrating cognitive recovery in primates with a genetically engi neered cell line of murine origin, which, as in the rat (Sinden, J. D., et al. Neuroscience 81:599-608: 1997) , reconstructed the damaged CA1 field. The identification of monogenic and complex genes responsible for disorders requires new approaches for delivering therapeutic protein genes to significant num bers of cells in vivo. A lentiviral-based vector pseudotyped with the VSV-G protein capable of infecting di viding and quiescent cells, was investigated in vivo by injecting highly concentrated viral vector stock into the striatum and hippocampus, of adult rats. Control brains were injected with a Moloney murine leukemia viral (MLV), adenoviral (ADV), or adeno-associated viral (AAV) vectors. Transduced volumes and cell densities were stereologically determined to provide a basis for comparison among different viral vectors and variants of the viral vector stocks. The lentiviral vector system was able to efficiently and stably infect quiescent cells in the primary injection site with transgene expression over the time of 6 months. Triple labeling showed that 88.7% of striatal cells transduced by the lentiviral vector were terminally differentiated neurons.
GENE TRANSFER IN TERMINALLY DIFFEREN TIATED CELLS WITH A LENTIVIRAL VECTOR
To determine the efficacy of gene transfer of a func tional gene, lentiviral vector expressing Bcl-xL, hNGF, and green fluorescent protein (GFP) was injected into the septum before transection of the fimbria fornix. Three weeks after lesion, BCL-xL-and hNGF-injected animals showed significantly higher numbers of rescued cholinergic neurons compared to control (GFP)-injected animals. Axotomy-induced neuronal death can be pre vented by lentiviral vector transfer of Bcl-xL and allows for localized methods to assess the function of neuro trophins and apoptotic factors, responsible for many neurodegenerative diseases.
The application of lentiviral vector encoding for tyro sine hydroxylase to the 6-OHDA animal model of Par kinson's disease also was investigated. Adult female Fisher 344 rats were unilaterally lesioned and tested for their apomorphine-induced rotational behavior. After in trastriatal injection of 4 ul highly concentrated lentiviral vector (TH) and for up to 6 months the rotational behav ior was statistically significantly reduced, compared to a lentiviral vector control group expressing GFP.
We conclude that lentiviral vector-based gene trans fer is able to achieve long-term transgene expression, which is able to compensate behavioral deficits in the rat model for Parkinson.
LENTIVIRAL VECTORS AS POTENTIAL GENE TRANSFER SYSTEM FOR CNS DISEASES
N. Deglon,* J. L. Tseng,* L. Pereira de Almeida,* V. Mittoux,^ J.-C. Bensadoun,* R. Zufferey,t D. Trono,t P. Hantraye.t and P. Aebischer* •Division of Surgical Research and Gene Therapy Cen ter, CHUV, Lausanne, Switzerland, tDepartment of Ge netics and Microbiology, C.M.U., Geneva, Switzerland, and ±URA CEA CNRS2210, SHFJ, DRM, DSV, CEA, Orsay, France Gene therapy approaches have been proposed to alter the progression of neurodegenerative diseases. However, adequate gene delivery systems are required to over come the presence of the blood-brain barrier, to evaluate candidate genes coding for secreted proteins or intracel lular molecules, to locally deliver these therapeutic agents in different CNS structures, and to allow longterm and sustained expression of the transgene. HIV1based lentiviral vectors, which fulfill these criteria, are currently being used to deliver neurotrophic factors or antiapoptotic genes, in animal models of Parkinson's and Huntington's disease.
In a first set of experiments, LacZ-or GDNF-expressing recombinant viruses were injected into the sub stantia nigra (SN) of adult rats. The animals were then subjected to a unilateral medial forebrain bundle axotomy (MFB). Seven days later, a significant neuropro tective effect was observed in the GDNF-treated ani mals, with 68.7 ± 1.8% TH-positive cells compared with 32.4 ±7.0% in control animals, injected with a LacZexpressing virus (p < 0.0003).
A protective effect of GDNF-and Bcl2-expressing viruses was also observed in a rat model of Huntington's disease. The intrastriatal injection of the recombinant vi ruses significantly reduced the lesion size (69% with GDNF and 95% with Bcl-2) resulting from chronic ad ministration of 3-nitropropionic acid.
These results further establish the value of lentiviral vectors to locally deliver potential therapeutic agents for CNS diseases. Acad. Sci USA 94:14083-14088, 1997; Mandel, R. J. et al., J. Neurosci. 18:4271^1284; 1998) . Transduced cells in the nigrostriatal pathway are almost exclusively neu rons (Bartlett, J. S., et al., Hum. Gene Ther. 9:1181 -1186 : 1998 Klein, R. L., Exp. Neurol. 150:183-194: 1998 ).
CELLULAR TROPISM OF AAV VECTOR-MEDI
Recombinant AAV virus expressing the EGFP (en hanced green fluorescent protein) reporter gene have been infused (2 pi containing 2.5 x 10 s infectious units in 10 min) in the rat brain parenchyma. The efficiency of gene transfer varied from one region to the other (glo bus pallidus > internal capsule > striatum). In the globus pallidus and the striatum, the GFP-positive cells had a neuronal morphology, whereas in the internal capsule, numerous glial cells were labeled. These data confirm the tropism of AAV vectors for neurons and suggest that glial cells can nevertheless be efficiently transduced in the absence of neurons. The number of labeled cells re mained stable up to 6 months postoperation, suggesting that sustained levels of therapeutic gene products can be obtained in the brain using AAV vectors. were used in the initial phase of the study (final n -30).
NEW SOURCES OR ALTERNATrVES-XENOGRAFTING

ALLOGRAFTS IN THE MINEPIG MPTP MODEL OF PARKINSON'S DISEASE
Animals were randomly assigned to one of five groups:
(1) Control, (2) MPTP (-) allograft, (3) MPTP (+) allo graft, (4) MPTP (+) allograft with immunosuppression, and (5) MPTP (+) allograft with immunosuppression and also co-grafting of immortalized HiB5 cells manipu lated to secrete GDNF («=2 ng GDNF/h/10 5 cells). Vascularized whole organ pig xenografts placed in the periphery are rejected by a rapid "hyperacute" pro cess that involves preformed antibody binding to the xeno-antigens on the donor endothelial cells with com plement activation. In the CNS xenografts are rejected by a different process that predominantly involves T-cell infiltration and rejection of the graft over the course of days to weeks. Modulation of the immune response with cyclosporin A greatly reduces the risk of graft rejection but still some grafts are rejected, which implies that Tcell processes may not be a complete explanation of the rejection process. We therefore investigated the role of complement and antibody in the rejection of embryonic porcine ventral mesencephalic grafts in the 6-OHDAlesioned rat.
THE REJECTION PROFILE OF PORCINE TO RAT VENTRAL MESENCEPHALIC XENO GRAFTS
Cell suspensions of E25 porcine VM tissue were transplanted into the dopamine-depleted striatum in a 6-OHDA rat and the rejection process followed over a 5week period in the absence of any immunosuppressive therapy. This process, along with the effect on amphet amine-induced rotation, was compared to a group of rats that received E14 VM rat allografts. The response to sham grafts was also recorded.
Xenografts, unlike rat allografts, had no effect on am phetamine-induced rotation. Grafts were found in all an imals, and although TH-positive cells were found in all allografted animals, they were only seen at the early However, during this period of time both a T-cell re sponse and humoral response were observed within the graft, which were then rejected over the next 25 days.
The loss of TH immunoreactivity preceded the actual loss of the graft, and the T-cell infiltrate appeared to precede the humoral response. Sham grafts induced no immune response and had no effect on rotation.
This study, therefore, clearly shows that porcine xe nografts induce both a humoral and cell-mediated re sponse, although the contribution of each to the rejection of the graft is unresolved. We have investigated the functional effects of por cine ventral mesencephalic neurons grafted into rats with 6-hydroxydopamine (6-OHDA) lesions. The po tency of cyclosporin A (CyA) in this model was investi gated, as well as cellular immune responses to the grafts at the end of the study (14 weeks). In a parallel study, immune responses to similar grafts were investigated at 2, 6, and 12 weeks in CyA-treated and untreated rats.
INTRASTRIATAL PORCINE VENTRAL MESEN CEPHALIC XENOGRAFTS IN RATS: IMMUNE RESPONSES AND FUNCTIONAL EFFECTS
Twenty-three rats with unilateral 6-OHDA lesions re ceived 4 ul of dissociated embryonic porcine ventral mesencephalon in the right striatum. Eighteen rats re ceived 10 mg/kg CyA IP daily and five rats remained untreated. All rats were tested for amphetamine-induced rotational behavior at 3-week intervals. Functional re covery was seen in a majority of the rats at 9 weeks.
Between 10 and 14 weeks, three immunosuppressed rats exhibited functional signs of graft rejection. At 14 weeks, 10 of 17 immunosuppressed and 2 of 5 untreated rats had functional effects. Grafts in recovered rats each contained 792-11,045 TH-positive neurons. The striata of rats with rejecting grafts contained high numbers of lymphocytes and activated microglial cells.
These findings show that porcine dopaminergic neu rons are able to mature, extend fibers into the rat stria tum, and restore a behavioral defect. However, CyA is not sufficiently effective in this model because four pre viously functional grafts were rejected during the study and four rats never developed functional grafts. CyA treatment also caused significant host toxicity. The im mune responses were characterized and compared for untreated and CyA-treated rats at the different time points (2, 6, 12, and 14 weeks) using stereologically ob tained cell counts for CD4, CD8, and NK cells and opti cal density measurements for microglial cells. The cellu lar response to discordant neural xenografts resembles a delayed type of hypersensitivity reaction, including NKand microglial cells, and is not fully prevented by CyA.
In conclusion, the use of porcine tissue for neural xenotransplantations is a promising alternative, but to achieve stable graft survival in discordant xenogeneic models (ultimately pig-to-human), a more effective im munosuppressive treatment or modification of the donor tissue is needed. This study attempted to elucidate and analyze the connection between the recipient inflammatory response to striatal injection and possible plastic response by the nigrostriatal dopaminergic innervation. Therefore, three different stimuli for the local inflammatory response in the intact rat striatum were employed: (1) a sham graft,
THE RELATION BETWEEN THE LOCAL IN FLAMMATORY/IMMUNE RESPONSE TO IN TRASTRIATAL GRAFTING AND ENHANCED PLASTICITY OF DOPAMINERGIC NIGROSTRI ATAL CONNECTIONS IN THE RAT
(2) quinolinic acid injection, and (3) The strongest and most reproducible inflammatory/ immune response was found in quinolinic acid recipients at all observation times (3, 7, and 28 days), but also in those recipients of discordant xenogeneic cells, where the grafts were rejected. In the rats with pronounced in flammatory response the dopaminergic nigrostriatal in nervation displayed strong increases in TH, DAT, and GAP-43 immunoreactivity as well as increased mRNA labeling to all three markers in the cells of the ipsilateral substantia nigra, as shown by in situ hybridization. Acti vated astroglial cells in the same striata displayed immu nohistochemically detectable levels of GDNF.
The activation of a local inflammatory/immune re sponse in the rat striatum leads to enhanced nigrostriatal dopaminergic innervation plasticity, which may be me diated by increased production and availability of dopa minergic trophic factors (e.g., GDNF). Rejection of intracerebrally grafted fetal pig neural tissue is known to occur in rats (Pakzaban, P., Isacson, O., Neuroscience 62:989-1001; 1994). We recendy re ported that fetal pig brain cells grown in primary culture induce a proliferative response in human T lymphocytes, while freshly isolated brain cells failed to induce such a response (Brevig, T., et al., Cell Transplant. 6:571-577; 1997 ). Here we report on the phenotype of the fetal pig brain cells most likely involved in the induction of the host cellular immune system. By flow cytometry, we show that fetal pig brain cells express major histocom patibility complex (MHC) class I antigens when grown in primary culture (serum-containing medium), while freshly isolated cells express neither MHC class I nor MHC class II antigens. A population of the cultured brain cells autofluoresced and stained positive for MHC class II antigens and CD 18, which is typical of macro phages. By confocal laser scan imaging, these cells were shown to have phagocytic activity. The nonautofluorescent cells were MHC class II negative, CD56 (NCAM isoform) positive, and contained the astrocyte marker GFAP. In these flow cytometry analyses, we found that primary glial cell cultures from E28 pig brains contain about 10-20% macrophages and 80-90% astrocytes. On the basis of autofluorescence, cell size, and cell granu larity, we are now separating cultured porcine fetal brain cells into astrocyte and macrophage populations by flow sorting. We have obtained populations of over 98% astrocytes and populations of over 70% macrophages.
To determine the human T-cell proliferation, the sorted cell populations are cocultured with mononuclear blood cells from healthy individuals. The status of these exper iments will also be presented. Although many trophic factors have proven inefficient in the nigral graft paradigm (e.g., NGF, BDNF, KFGF, , several studies now indicate that both KFGF and GDNF effectively enhance mesencephalic transplant survival. Trophic factor withdrawal is associated with apoptosis in the developing nervous system, and indeed, there is also evidence for apoptosis in nigral grafts. Our recent data show that inhibition of caspases results in a marked increase in dopaminergic neuron survival, while interference with the apoptotic process through overex pression of bcl-2 is ineffective.
PORCINE XENOGRAFTS IN PARKINSON'S DIS EASE AND HUNTINGTON'S DISEASE
In conclusion, an arsenal of effective neuroprotectants is now available, providing reason for optimism and reducing demands on human neural donor tissue in the future. In this study, cell suspensions were prepared from em bryonic rat mesencephalic tissue with or without 5 uM U-10 present during the preparation. This concentration of U-10 has in a preliminary culture study has been shown to be beneficial to dopaminergic neurons. In the present in vitro experiment, cell suspensions were kept at room tem perature for 4 h followed by a 37°C incubation for addi tional 20 h. This paradigm has been developed to mimic the first 24 h of the grafting procedure. At 4, 9, and 24 h after tissue dissociation, the survival of mesencephalic neurons, as well as the ratio of apoptotic and necrotic neurons, was studied with the dyes ethidium homodimer and Hoechst nuclear stain. We also measured the degree of DNA fragmentation, a feature of apoptosis, in the cell suspensions. In another set of experiments, we trans planted mesencephalic cell suspensions (with or without 5 uM U-10) to adult rat striatum. Four weeks after trans-plantation, the numbers of surviving dopaminergic neu rons were evaluated using tyrosine hydroxylase immunocytochemistry. Results are in progress. In addition to its neuroprotective actions, FK506 pro motes differentiation and neurite outgrowth in cultured neurones and accelerates functional recovery following nerve crush by accelerating axonal regeneration. These neurotrophic actions are not mediated via calcineurin as they are shared by rapamycin and nonimmunosuppressive derivatives of FK506 while Cs-A exhibits little or no neurotrophic activity (Gold, et al., Neurosci. Lett. 241:25-28; 1998) .
EFFECTS OF A NOVEL LAZAROID U-101033E
NEUROPROTECTIVE AND NEUROTROPHIC
The unique combination of immunosuppressive, neu roprotective, and neurotrophic actions together with its ability to cross the BBB suggests that FK506 may be a suitable adjunct to graft survival for intracerebral im plants. periments. According to these results, freely moving rats were treated with HFS (intensities of 150, 225, or 300 uA). Similar results with delayed and intensity-depen dent increases of DOPAC to maximum 39% and of HVA to maximum 25% were observed, whereas no changes of extracellular dopamine and 5-HIAA were found.
POTENTIAL NEUROPROTECTIVE EFFECTS OF SUBTHALAMIC NUCLEUS INACTIVATION IN A RAT MODEL OF PARKINSONISM
Our results indicate that HFS of the STN produces a delayed and stable increase of dopamine metabolites in the striatum, whereas stimulation with 20 Hz does not influence the measured parameters in vivo. We conclude that the dopaminergic system in the striatum is involved in the mechanism of STN-HFS. Several experimental studies suggest that trophic fac tors may slow the progression of neurodegenerative dis eases or prevent the neural degeneration in acute injury such as trauma or ischemia. However, sustained and controlled delivery of neurotrophic peptides in a discrete region of the brain remains a challenging area of re search. Among the strategies developed, the implanta tion of drug-releasing polymeric devices is gaining considerable attention. Our group has focused on poly(D,L,lactide-co-glycolide) (PLGA) biodegradable microspheres. Due to their size, these microparticles can be easily implanted by stereotaxy in discrete and func tional areas of the brain without causing damage to the surrounding tissue. Experimental studies and the long history of the clinical use of PLGA, particularly as sur gical sutures, has demonstrated its excellent histocom patibility. In the brain, PLGA microspheres elicit only a weak and nonspecific astroglial and microglial reaction. The release kinetic, regulated by a combination of diffu sion and degradation phenomena, can be modified and adapted to suit clinical purposes. This new approach was first developed for interstitial chemotherapy of brain tu mors and is nowadays in clinical evaluation.
LIPOSOME-MEDIATED GDNF GENE TRANS
PLGA microspheres (30 um diameter), allowing a controlled release of bioactive nerve growth factor (NGF) in vitro, at least during 1 month, were prepared. In vivo, NGF was still detected in the microspheres 2.5 months after implantation, the microspheres being to tally degraded at 3 months.
We have studied these microspheres in two rat mod els of neuronal injury. In the first one, axotomy of the cholinergic basal forebrain by section of the fornix-fim bria, microspheres were implanted concomitantly to the lesion, close to the septal nuclei. No adverse effect was observed on neurons close to the microspheres, and a subtantial rescue of the cholinergic neurons was ob served with NGF-releasing microspheres. In the second model, an excitotoxic lesion of the striatum, micro spheres were implanted in the striatum 1 week before quinolinic infusion and the animals were sacrificed 2 weeks later. NGF-releasing microspheres reduced by 40% the lesion size and a marked neuronal sparing was noted. This protection principally involved the choliner gic interneurons, but also neuropeptide Y/somatostatin interneurons and GABAergic neurons.
These results indicate that biodegradable micro spheres could be used for neurotrophic therapy. Animals received a total dose of 56 ug 6-OHDA bi laterally, which was distributed over four injection sites per striatum. Three months after lesion surgery, part of the animals received unilateral respectively bilateral transplantation of rat E14 ventral mesencephali. Prior to and after lesion surgery as well as 2 and 6 months after transplantation spontaneous and drug-in duced behaviors were investigated. This included over night activity, rotation, forelimb akinesia, and skilled forelimb use.
BEHAVIORAL CHANGES AFTER TERMINAL STRIATAL 6-OHDA LESION AND TRANSPLAN TATION OF DOPAMINERGIC EMBRYONIC MI-CROGRAFTS
Following 6-OHDA lesion surgery, animals showed diminuished scores in overnight activity, forelimb akine sia in the stepping and side-falling test, and impairment in skilled forelimb use. Animals with unilateral DA micrografts showed a trend towards improvement in the backhand stepping test and decreased success in skilled forelimb use on the side contralateral to the grafts. High contralateral rotational scores were seen after adminis tration of amphetamine. Bilaterally transplanted animals showed improvement in forelimb akinesia and impaired performance in skilled forelimb use on both paws. The results were stable. In the other tests, no significant changes were seen after transplantation.
In comparison with behavioral data derived from dif-ferent lesion sites in the striatum, the pattern of behav ioral changes after terminal 6-OHDA lesions reveal more information about the functional organization of the rat basal ganglia system. Following transplantation of DA micrografts the animals demonstrate behavioral changes that differ from previous transplantation studies with medial forebrain bundle lesions. A bilateral influ ence of the grafts has to be considered. Different restor ative approaches including transplantation at other sites and with other cell types as well as application of growth factors are options for further investigations in this model. In previous studies we have demonstrated functional recovery following transplantation of embryonic nigra into the striatum of marmosets with unilateral 6-OHDA lesions of the nigrostriatal pathway on tests of amphet amine-induced rotation and on a task in which the mon keys reached into tubes to retrieve food (Annett, L. E., et al., Exp. Neurol. 125:228-246; 1994 ; Annett, L. E., et al., Exp. Brain Res. 103:355-371; 1995) . In the pres ent study, marmosets were trained to hold down and then release a lever as they reached for a target stimulus on a touch-sensitive screen. Performance with each hand was assessed on alternate daily sessions. Unilateral 6-OHDA lesions profoundly impaired performance of this task so that monkeys failed to complete trials with the contralateral hand. The deficit persisted for up to 15 months in lesion control monkeys (n = 6). Grafts of mar moset embryonic nigra were made into the dopaminedepleted striatum 8 weeks after the 6-OHDA lesion. The cell suspension grafts were either of one (n = 6) or 2-4 (i.e., all the embryos from a single pregnancy) embry onic nigra per recipient (n = 6). Graft placements were distributed throughout the striatum, including the cau date nucleus, putamen, and nucleus accumbens. Trials completed with the contralateral hand improved signifi cantly in the grafted marmosets overall compared with the lesion controls (p<0.01). However, the extent and rate of recovery were highly variable between subjects, in some cases not becoming evident until between 7 and 12 months after grafting. Graft survival was also vari able, ranging from 16 to 1820 (mean 606 ±284) +TH cells in the striatum in the single donor group and 548 to 8730 (mean 4498 ± 1604) in the multiple donor group. Good graft survival was necessary, but not suffi cient, for recovery of function on the touch screen task. Ten parkinsonian patients were followed 1-4 years following a sequential bilateral allotransplantation of mesencephalic embryonic neurones. All had severe Par kinson's disease and were staged IV or V in defined "off according to the Hoehn and Yahr scale before sur gery. Four patients received mesencephalic tissue from one embryo (group I: patients 1, 3, 6, 7), at least in one side; the remaining received mesencephalic tissue from 2-4 embryos in both hemispheres (group II: patients 2, 5, 8, 9, 10, 11) . Significant and persistent clinical im provements with a reduction of daily "off and levodopa intake were observed only in patients from group II, but with large differences between cases. A follow-up for almost 5 years in one patient indicates that more than 80% of antiparkinsonian drug dosage may be withdrawn with a peristent correlative improvement of dyskinesias, and that the second engraftment led to a further im provement. No cognitive decline was recorded in the co hort, although it was observed in one patient, together with a severe depression. The evolution of striatal levo dopa uptake capacity was measured yearly, and can be correlated, at least in part, with clinical results. 
NIGRAL GRAFTS RESTORE REACHING TO TARGETS ON A TOUCH-SENSITIVE SCREEN IN
SEQUENTIAL BILATERAL ALLOTRANSPLAN TATION OF MESENCEPHALIC EMBRYONIC NEURONES IN SEVERE PARKINSON'S DIS
HUNTINGTON'S DISEASE
NEUROPROTECTIVE AND RECONSTRUCTIVE THERAPEUTIC STRATEGIES IN MACAQUES CHRONICALLY TREATED WITH 3-NITROPRO-PIONIC ACID
U421, IM3, Faculte de Medecine, 8 Rue General Sarrail, 94010 Creteil cedex, France
Using a chronic primate model that reproduces key clinical features of Huntington's disease (HD) and the neuronal dysfunction-to-degeneration progression, we tested the therapeutic potential of two different and com plementary approaches, namely a substitutive strategy using striatal allografts and a neuroprotective strategy using sustained intracerebral CNTF delivery by encap sulated genetically modified baby hamster kidney cells.
Allograft experiments: In this study, six Macaca fascicularis monkeys were treated chronically for 8 months with daily injections of the neurotoxin 3-nitropropionic acid (3NP) to model a late-stage HD. At the end of the treatment, clinical assessment as well as performances in the object retrieval detour task (ORDT) of the six 3NP-treated animals were compared to that of six con trol animals to ascertain the efficacy of the 3NP-induced treatment. All 3NP-treated animals displayed a signifi cant increase in the incidence of abnormal movements including limb and trunk dyskinesia, dystonia, and cho rea, as well as a severe impairment in the ORDT. Four to 9 months later, half of the animals (n -3) received bilateral allografts derived from the lateral ganglionic eminence of E51-E55 macaque embryos implanted into the precommissural caudate nucleus and the pre-and postcommissural putamen. The second group of animals (sham, n -3) received the same surgical procedure ex cept that only a saline solution was stereotaxically in jected in similar caudate-putamen regions. Clinical ob servations as well as performances of both groups of animals in the ORDT were then obtained monthly over a 5-month period postgrafting. As early as 2 months postsurgery, grafted animals showed a significant ame lioration of their performances in the ORDT test, whereas sham-operated animals did not show any signif icant improvement. This difference between groups was maintained throughout the remainder of the experiment. The clinical analysis indicated that the incidence of dys tonia, but not that of limb dyskinesia, was significantly reduced in the grafted animals, compared to the shamoperated macaques, beginning 4 months postgrafting. At completion of the behavioral study, the histological analysis confirmed the presence of a severe depletion of calbindin-positive medium-sized spiny neurons in both caudate nucleus and putamen of all 3NP-treated animals.
CNTF chronic in situ delivery: Substitutive therapy using fetal striatal grafts in rodent and primate models of HD have already demonstrated obvious beneficial ef fects on motor and cognitive indices. However, such ap proach may not be adapted to the treatment of early (grade I) HD patients in which cognitive and motor
symptoms may be observed in the absence of obvious striatal neuronal loss. In this context, a neuroprotective strategy using neurotrophic factors such as ciliary neuro trophic factor (CNTF) could be more adapted. Six Ma caca fascicularis monkeys were treated chronically for 5 months with daily injections of 3NP. After 10 weeks of treatment, encapsulated CNTF-producing fibroblasts were implanted bilaterally into both lateral ventricle and medial putamen, and the 3NP neurotoxic treatment was pursued for an additional 3-month period. Sham-oper ated animals receiving encapsulated native BHK cells and the same chronic 3NP treatment were used as con trols. Motor and cognitive performances were assessed at various time points (i.e., prior 3NP treatment, follow ing a 10-week 3NP treatment, and 1, 2, and 3 months following implantation of the capsules). After 10 weeks of 3NP treatment, before implantation of the capsules, all 3NP-treated animals displayed a significant hyper kinesia and a severe frontal-type cognitive impairment. Following surgery, repeated motor and cognitive assess ments showed that whereas the sham-operated animals were aggravating their motor and cognitive deficits un der the continuation of the 3NP treatment, a progressive but highly significant recovery in both motor and cogni tive deficits was observed in the CNTF group of ani mals. This difference between groups was maintained throughout the remainder of the experiment. Histologi cal analysis performed 3 months postimplantation dem onstrated a neuroprotective effect of the treatment against 3NP-induced loss in striatal calbindin neurons.
These findings obtained in a chronic primate model of HD indicate that striatal allografts derived from the lateral ganglionic eminence can have a strong therapeu tic potential in late-stage HD, ameliorating both cogni tive and motor aspects of this disorder. The findings ob tained with CNTF indicate that chronic delivery of low doses of this trophic factor to the HD caudate-putamen complex has a strong therapeutic potential. The neuro trophic factor was not only neuroprotective for striatal GABAergic neurons, as previously shown, but could also improve the cognitive and motor status of monkeys that were continuously challenged with the mitochon drial toxin 3NP.
EFFECTS OF CILIARY NEUROTROPHIC FAC TOR ON EXCITOTOXICITY AND CALCIUM-IN DUCED DEATH IN CULTURED EMBRYONIC STRIATAL NEURONS Asa Petersin and Patrik Brundin Section for Neuronal Survival, Wallenberg Neurosci ence Center, Department of Physiology and Neurosci ence, Lund University, Solvegatan 17, 22362 Lund, Sweden
Ciliary neurotrophic factor (CNTF) has a protective effect on the striatum in animal models of Huntington's disease, and there are now ongoing clinical trials in Eu rope using this growth factor. However, the mechanism through which it exerts its effect is not clear.
In this study, we show that there is a concentrationdependent protective effect of CNTF (10, 100, and 200 ng/ml) against /V-methyl-D-aspartate (100 mM)-mediated excitotoxicity for 24 h on striatal neurons cultured for 7 days in vitro (DIV), and that CNTF has to be added more than 0.5 h before the insult for the effect to occur. This suggests that the protective mechansim of CNTF does not involve interference with the glutamate recep tors, but more likely requires gene/protein expression to be exerted. Our results also indicate that the action of CNTF is directly on the striatal neurons as only 1% of the cells constituted glial cells.
We have also shown that the effect of CNTF against glutamate-induced excitotoxicity (1 and 2 mM of gluta mate administered for 24 h at 12 DIV) is dependent on the concentration of glutamate with a protective effect more evident at a low-grade excitotoxic insult (1 mM). Finally we saw no effect of CNTF on toxicity induced by the calcium ionophore A23187 (1 and 2 mM) for 4 h after 8 DIV, which suggests that the mechanism of action of CNTF does not involve the calcium buffering capacity of the neurons.
In summary, CNTF has a protective effect directly on striatal neurons against excitotoxicity mediated by both glutamate and NMDA, further supporting the idea that it may be of therapeutic value in Huntington's disease. We are using a line of transgenic mice expressing exon 1 of the human Huntington's disease (HD) gene, carrying 141-157 CAG repeat expansions (R6/2, Mangi arini, et al., Cell; 1996) to evaluate the functional effects of striatal transplants in a rodent model of HD that may be more relevant (or at least complementary) to the hu man disease than the conventional striatal excitotoxic le sion models.
CHARACTERIZATION OF STRIATAL GRAFTS ON PROGRESSIVE MOTOR DEFICITS IN R6/2 MICE TRANSGENIC FOR THE HUMAN HD MU TATION
In our first experiment, we evaluated the survival of embryonic murine striatal grafts (whole eminence) and found that the grafts survived and differentiated at least as well in the R6/2 striatum as in the wild-type mice. This suggests that the expression of the expanded CAG repeat, which leads to the pathological profile in mice (including neuronal intranuclear inclusions similar to the human disease), does not compromise the survival of striatal grafts. However, the grafted animals in this ex periment exhibited no functional improvements in body weight loss or behavior in an open field. This may be attributable to any one of a number of possibilities in cluding the fact that: (i) the grafts were only implanted unilaterally; (ii) implantation was relatively late (into 9-10-week-old hosts), thus not giving the grafts time to develop; (iii) behavioral tests were insufficiently sensi tive; (iv) the transgenic model itself may be invalid; or (v) striatal grafts will not provide a useful therapy for progressive striatal degeneration, including HD. Clearly, the former possibilities (i)-(iii) need to be ex cluded before concluding the invalidity of the model (iv) or the nonfeasibility of transplantation approach per se (v).
In the second series of experiments, we have devel oped and validated a series of behavioral tests of motor coordination and sensorimotor function in order to char acterize the progression of the motor phenotype. These include: (i) body weight, as an index of general health and nutritional status; (ii) open field, as an index of ac tivity and exploration; (iii) raised bridges, as an index of coordination and balance; (iv) rotarod, as an index of coordination and balance; (v) footprint, as an index of walk, gait, and stride; (vi) water tank, as an index of swim speed and coordination; and (vii) acoustic startle and prepulse inhibition, as an index of motor reactivity and sensory gating. We observe a progressive deteriora tion of performance on all measures between 5 and 14 weeks of age. Several of the tests (raised bridges, rotarod) have multiple levels of difficulty: not only is the magnitude of the deficit greater the more diffi cult the task, but also the age of onset is earlier. The most sensitive tests (high-speed rotarod, swimming, nar row square beam) reveal subtle deficits as young as 5 weeks, whereas the overt neurological symptoms are not apparent until > 8 weeks. Body weight stabilizes at -10 weeks and goes into decline from -12 weeks of age.
The third set of experiments is comparing the perfor mance of R6/2 mice with and without striatal grafts im planted bilaterally at 5 weeks of age on a subset of the measures of motor capacity. The study is still in prog ress, and it is too early at this point to determine whether the early bilateral grafts will be functionally protective in the transgenic mice. These data show that striatal grafts can survive as readily in HD transgenic mice as in the normal mouse brain, and validate a series of sim ple and reliable quantitative tests of motor deficits with high reliability and low variance. The extent of function recovery achievable by striatal grafts in this animal model has yet to be fully determined. Rosser, L. H. Watkins, B. Sahakian, G. Berrios, J.  R. Hodges, and S. B . Dunnett Cambridge Centre for Brain Repair, Cambridge CB2 2PY, UK
THE CAMBRIDGE HUNTINGTON'S DISEASE COHORT: PREOPERATIVE UHDRS ANALYSIS
A. E.
The UK branch of NEST-HD comprises six centers (Aberdeen, Belfast, Cambridge, Cardiff, London, and  Manchester) , five of which have been actively engaged in the assessment of patients using the CAPIT-HD pro tocol. The results obtained from this study will be used in several ways: to document the course of early Hun tington's disease; to select patients for transplantation studies; and to define outcome measures for the trans plantation program. Patients selected for primary human fetal tissue transplants will have the surgery performed in Cambridge, where human fetal tissue is currently be ing collected according to UK ethical guidelines. The Cambridge cohort comprises 23 patients with early Hun tington's disease, in whom the average age is 49.3 (SD = 10.6) and the male to female ratio is 16:7. Seven pa tients have been followed for 3 years or more, seven for 2-3 years, four for 1-2 years, and the remainder for up to a year. Group analysis revealed that total motor score deteriorated in a linear fashion over time, F(l, 73) = 65, p< 0.001; r = 0.9. For all subscores of the motor UHDRS correlation coefficient (r) was greater than 0.8, with the exception of posture (r = 0.75) and the Luria tri step (r = 0.08). All three functional scales-activities of daily living, independence, and the Fahn-showed lin ear deterioration. Group analysis of cognitive scores re vealed that tests involving speed (motor or cognitive) declined in a linear fashion, whereas tests of memory remained stable. Surprisingly, classical tests of frontal function, such as verbal fluency and the Wisconsin card sorting test, showed little change in this cohort. In order to fully understand the changes occurring in early Hun tington's disease, we have analyzed these data in indi vidual cases as well for the whole group.
EMBRYONIC DONOR AGE AND DISSECTION INFLUENCES STRIATAL GRAFT DEVELOP MENT AND FUNCTIONAL INTEGRATION IN A RODENT MODEL OF HUNTINGTON'S DISEASE
Colin Watts MRC Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK
The aim of this investigation was to optimize harvest ing of embryonic striatal donor tissue by evaluating the interaction between embryonic donor age and embry onic dissection.
Seventy animals were lesioned with quinolinic acid and allocated to seven groups of 10 animals. Groups 1, 2, and 3 received whole, lateral, and medial ganglionic eminence tissue (WGE, LGE, and MGE), respectively, from E14 donors. Groups 4, 5, and 6 received corre sponding tissue from E16 donors. Group 7 was ungrafted control. Amphetamine-induced rotation was per formed prior to and for 12 weeks postgrafting. Paw reaching was analyzed from trials at 3 and 6 months postgrafting. On completion of behavioral testing retro grade tracing of connections to the globus pallidus was combined with electrical stimulation of the fronto-parietal cortex to induce immediate early gene expression, as a marker of physiological excitation, within the grafts.
Postmortem analysis of the grafts revealed LGE grafts from E14 donors to be the smallest and to contain the smallest volume of striatal tissue but to have the highest proportion (80%) of striatal tissue within the graft. The volume, but not the proportion, of AChE-pos itive striatal tissue was found in E14 WGE grafts.
There was little difference between LGE and WGE grafts from El6 donors. Immediate early gene expression was found in a small population of cells weakly stained with retro grade tracer in E14 WGE and LGE grafts only, suggest ing physiological excitation of efferent projection neu rons. Rotation bias was significantly attenuated by E14
LGE grafts only. Retrieval skill was improved on the contralateral side in animals grafted with E14 medial ganglionic eminence tissue (MGE) tissue compared to lesion controls.
The results suggest that WGE El4 donor tissue may be the best available choice. MGE tissue may have an unrecognized role in graft-mediated behavioral re covery.
ISSUES IN TRANSPLANTATION FOR HUN TINGTON'S DISEASE
K. Kieburtz University of Rochester Medical Center, Rochester, NY
Transplantation of neuronal cells to the striatum has been suggested as a potential therapy for Huntington's disease. The apparent success of fetal transplantation in Parkinson's disease has given additional emphasis to ex ploring this option in other neurodegenerative disorders. Despite the rationale and preclinical research, largescale clinical trials of transplantation are not advisable, until several issues have been resolved. First, there must be optimization of the technical procedures for obtain ing, storing, and delivering transplantable tissue, primar ily human fetal tissue. Important factors yet to be deter mined are the most appropriate fetal age, appropriate dissection procedures, optimal method of storing and de livering the cells (block, suspension), and the optimal implantation sites (caudate, putamen) and whether there should be multiple injections at each site. A second area that has not received sufficient attention is the adequacy of subject informed consent. There are tremendous pres sures to participate in any experiment for Huntington's disease, but the adequacy of informed consent has not been fully explored. In addition, in the setting of possi ble xenotransplantation (porcine fetal tissue) the need for obtaining informed consent from family members is raised, because of concerns for potential transmission of infectious agents through intimate contact. Third, al though some longitudinal clinical assessment measures have been developed, better measures of clinical disease progression are necessary. A CAPIT-HD protocol was an initial suggestion for longitudinal assessment of pa tients undergoing transplantation but updated modifica tions are needed. Specifically, one optimal primary clini cal outcome measure derived from such a battery of tests needs to be identified to establish whether transplanta tion is effective. Fourth, there has been extensive debate on the use of placebo controls in surgical trials. Many investigators have expressed concern that concurrent placebo controls are not appropriate for such an inter vention. But is it appropriate to proceed without con trols, risking the confounding influence of placebo ef fects and bias?
Taken together these concerns suggest that further preclinical research and thoughtful deliberation are nec essary to identify optimal technical aspects of transplan tation. Once these parameters are established, initial pi lot studies to examine safety, tolerability, and feasibility may be considered. Fetal neural grafts of striatal tissue are currently un der study for the treatment of Huntington's disease (HD) in at least three different groups, including ours. The validity of this therapeutic approach, from a general viewpoint, is based upon three main types of data. First, there is now a wide agreement on the fact that HD is primarily characterized by vulnerability of a specific neuronal population ("medium-size spiny" neurons) in the striatum, even though subsequent alteration is ob served in widespread cortical and subcortical areas. Sec ond, a very large set of experimental data, obtained in rats and nonhuman primates, has demonstrated that transplanted fetal striatal cells are able to substitute, ana tomically and functionally, for previously injured host striatal neurons. Recent data obtained using allografts in macaques previously treated by systemic administration of 3-nitropropionic acid show, in particular, the ability of this procedure to elicit cognitive recovery in a frontaltype test (Object Retrieval Detour Task), in addition to alleviate motor symptoms. Third, clinical neural trans plantation has proven safe and effective, in the hands of skilled researchers, for the treatment of patients with Parkinson's disease.
FETAL NEURAL TRANSPLANTATION FOR
Setting up of the clinical program for HD in Creteil has required two specific steps to be taken: (i) perform ing a number of complementary experiments within the framework of an explicit "preclinical protocol" aimed at answering questions directly related to the clinical appli cation, and (ii) creating clinical scales for the follow-up of the patients, as these scales were essentially missing. We have, in particular, performed a comprehensive lon gitudinal cognitive assessment to provide a better esti mate of the natural history of the disease. Fifteen pa tients, even though at early stages (mostly I), exhibited cognitive deterioration at entry and, over the course of the study (2 years), displayed significant decline in many tasks assessing different cognitive functions. These included, in particular, attention, planning, lan guage production, and visuo-spatial integration. Memory functions, which were noticeably altered at entry, did not express a significant decline because of conspicuous retest effects. Correlation analyses point to a coherent decline of functions subserved by the fronto-striatal pathway systems.
Five patients were recruited for a first clinical trial that essentially aimed at assessing safety and feasibility. There were no adverse effects of a unilateral fetal striatal allotransplant into the caudate and the putamen nuclei (four or five tracks). Several informations, calling for caution in surgical protocols involving HD patients, were nevertheless obtained. Patients, and caregivers, were very sensitive to stress and anxiety, as exemplified by variations in performance of some patients during the 3 months that separated inclusion into the protocol and surgery, and by mood disturbances in caregivers after surgery. Despite recruitment of patients at early stages, placement of transplants was often hampered by striatal atrophy. Patients' and relatives' expectations, though as lowered as possible by careful explanation all along the protocol, were very high and consequences may become worrisome in the long term, if the results do not fulfill the hopes. Multiple system atrophy of the striatonigral degenera tion (MSA-SND) type is a common cause of atypical parkinsonism. In this disorder two related neuronal sys tems, substantia nigra and striatum, that have been stud ied in great detail experimentally, undergo degeneration. MSA-SND appears highly suitable for the development of an animal model: (1) because the neuropathology of the disease that serves as gold standard is known to a large extent, and (2) because animal models of either the nigral (PD-like) or striatal (HD-like) lesion are estab lished and provide a baseline for the optimal MSA-SND model.
Previous attempts to mimick MSA-SND pathology in rodents have included sequential injections of 6-hy droxydopamine (6-OHDA) and quinolinic acid (QA) into medial forebrain bundle and ipsilateral striatum, re spectively (double toxin-double lesion approach). Pre liminary evidence in rodents subjected to such lesions indicates that embryonic transplantation may partially reverse drug-induced rotational asymmetries. The neuro protective potential of embryonic striatal grafts follow ing unilateral dopaminergic denervation and prior to in trastriatal QA injection is presently under investigation in the sequential lesion model. In vivo MRI and behav ioral data suggest graft-induced structural, but absent functional, protection. Intrastriatal injections of mito chondrial toxins such as 3-nitropropionic acid (3NP) and l-methyl-4-phenylpyridinium (MPP+) in rodents result in (secondary) excitotoxic striatal lesions and neuronal degeneration of ipsilateral substantia nigra pars compacta, thus producing MSA-SND-like pathology by a simplified single toxin-double lesion approach.
A recent study at our institution failed to demonstrate recovery of rotational asymmetry and paw reaching defi cits in animals with marked nigrostriatal lesions induced by intrastriatal 3-NP injection. MSA-SND animal mod els require further optimization by comparative studies of human SND pathology and rodent striatonigral le sions. Furthermore, partial MSA-SND models with lim ited dopaminergic denervation and striatal destruction may be more promising for interventional therapies such as embryonic grafting or growth factor delivery. In order to achieve a complete lesion of nigral and striatal neurons corresponding to end-stage SND, a sec ond lesion into ipsilateral striatum or MFB was added subsequently, depending on the initial target. Paw reach ing and stepping tests were repeated 4 and 6 weeks after the second lesion.
ALTERATIONS OF PAW REACHING AND STEP PING IN RATS RECEIVING SEQUENTIAL LE
There was a significant reduction of mean number of food pellets eaten with the contralateral compared to the ipsilateral paw in both animals with initial nigral (con tralateral 1.8 ±0.9 vs. ipsilateral 5.3 ±2.1, p< 0.005) and striatal lesions (contralateral 1. 5 ± 1.8 vs. ipsilateral  4.2 ± 3.4, p < 0.01) . The number of contralateral-adjusting backhand steps was significantly reduced only in an imals with initial nigral lesions (contralateral 4.9 ± 2.7 vs. ipsilateral 15.8 ± 4.3, p < 0.005). There was no sig nificant change of impaired paw reaching following the second complementary lesion in either group. Contralateral-adjusted stepping deteriorated significantly only in animals with sequential striato-nigral lesions (first lesion 9.5 ± 4.2 vs. second lesion 3.7 ± 1.6, p < 0.005).
Our data suggest that paw reaching deficits can be induced by either nigral or striatal lesions without signif icant additive effects. In contrast, stepping behavior ap pears to be sensitive to nigral, but not striatal, lesions. Reversal of paw reaching deficits in the sequential SND rat model may therefore require both nigral and striatal grafts whereas stepping impairment may be improved with nigral grafts alone. grafting or xenografting will be required. The current status of generating high numbers of oligodendrocyte pro genitors from these sources will be reviewed. Data will also be presented that indicate progenitor cells trans planted into the normal adult nervous system do not mi grate long distances, and high density of astrocytes in ar eas of demyelination may limit remyelination. It may therefore be difficult to remyelinate large areas of chronic demyelination even when ways have been found to ex pand oligodendrocyte progenitors in vitro prior to trans plantation unless ways can be found to enhance migration and inhibit premature differentiation. Conditionally immortalized clonal stem cell lines are a promising source of donor tissue for neural transplan tation because they avoid the ethical and practical pit falls of fetal grafts, and have the potential to develop into appropriate cells in situ in response to inductive host signals. We have shown that grafts of MHP36 cells derived from the H2Kb-tsA58 "immortomouse" neuroepithelium reverse spatial learning deficits in rats with ischemic CA1 cell loss (Sinden, J. D., et al., Neurosci ence 81:599-608; 1997), and conditional discrimination deficits in marmosets with excitotoxic CA1 lesions. Moreover, MHP36 cells repopulated the area of CA1 cell loss in a species-specific manner. In rats they recon stituted the narrow, tightly packed pyramidal cell layer, whereas in marmosets they adopted the sparse and evenly spaced cell distribution characteristic of primate brain. These findings in a model of damage to a pointto-point circuit suggest that MHP36 cells achieve their functional effects by circuit reconstruction. We have ad ditionally investigated the effects of MHP36 cells in a model of more diffuse damage. Implanted into the termi nal regions of the forebrain cholinergic projection sys tem (cortex and/or hippocampus) in rats with bilateral AMPA lesions of the basal forebrain and medial septal area, or with large unilateral basal forebrain lesions, both resulting in marked deficits in spatial learning in the water maze, MHP36 grafts produced substantial im provement to control level. These findings in two such diverse lesion models raise the possibility that MHP36 grafts may engage multiple recovery processes, includ ing localized repair, transmitter release, and astrocytic trophic support. The robust effects of MHP36 grafts in rodents and primates with hippocampal damage signpost our first clinical target (pending development of equiva lent human-derived cell lines): recovery of memory in patients with impairments after interruption of cerebral blood flow (e.g., after cardiac arrest, heart bypass sur gery, or coronary artery occlusion) (Grubb, N. R., et al., Br. Med. J. 313:143-146; 1996).
TRANSPLANTATION OPTIONS FOR REMY-
